Vijaya Diagnostic Centre Limited announced the outcome of its Board meeting held on February 13, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2025. Key leadership changes include the appointment of a new CFO, CTO, and COO, alongside the addition of two Non-Executive Independent Directors. The Board also noted the resignation of the previous CFO.
Outcome of Board Meeting on February 13, 2026
The Board of Directors of Vijaya Diagnostic Centre Limited convened on Friday, February 13, 2026, to review and approve several critical items related to governance and operational management. The meeting commenced at 12:30 P.M. and concluded at 02:30 P.M. (IST).
Financial Results Approval
The Board formally considered and noted the Unaudited Standalone and Consolidated Financial Results of the Company for the period encompassing the third quarter and the nine months ended December 31, 2025.
Key Management Appointments
Following recommendations from the Nomination and Remuneration Committee, the Board approved the following key managerial appointments, effective February 13, 2026:
- Mr. Ankit Shah appointed as the Chief Financial Officer (CFO) and Key Managerial Personnel. Mr. Shah holds significant expertise in corporate finance, strategic planning, and investor relations, having previously served as Group CFO at Incor Hospitals Private Limited.
- Mr. Sai Siva Prasad appointed as the Chief Technology Officer (CTO). Mr. Prasad is a seasoned technology leader with over two decades of experience driving large-scale digital transformation across sectors including Healthcare and BFSI.
- Mr. Venkata Siva Rama Raju Vegesna appointed as the Chief Operating Officer (COO). Mr. Vegesna is a Chartered Financial Analyst with prior experience at Krishna Institute of Medical Sciences Limited (KIMS Hospitals).
Furthermore, Mr. Ankit Shah has been authorized to handle disclosures related to material events to the stock exchanges under Regulation 30(5).
Changes in CFO Position
The Board formally noted the resignation of Mr. S. Ramachandra Reddy from the position of Chief Financial Officer (CFO), effective February 13, 2026. This step down is due to organizational restructuring, and Mr. Reddy will continue to serve the Company in his role as General Manager – Finance & Accounts to ensure a smooth transition.
Appointment of Additional Directors
The Board also approved the appointment of two additional directors, subject to shareholder approval:
- Mr. Ravi Shankararamiah (DIN: 00180746) appointed as a Non-Executive-Independent Director for a period of five (5) years. Mr. Shankararamiah is a senior and highly accomplished Senior Advocate with extensive experience in taxation and corporate law.
- Dr. Sasikala Paruchuri Kola (DIN: 00129614) appointed as a Non-Executive-Independent Director for a period of five (5) years. Dr. Kola is a highly experienced Consultant Gynaecologist and Obstetrician with over three decades of clinical and academic experience.
Employee Stock Option Plan (ESOP) Grant
The Board approved the grant of 1,15,000 Employee Stock Options (ESOPs) under the “VDCL Employee Stock Option Plan 2018.” These options, convertible into 1,15,000 equity shares of face value ₹1/- each, are being granted at an Exercise Price of ₹809/- per option. This represents an average closing price discount of 20%.
The options vest starting after one (1) year from the grant date, and the exercise period is Ten (10) years from the grant date. The current grant is specifically being made under ESOP scheme-5, targeting employees in Support functions (Finance & Accounts, IT, Strategy, Operations, etc.).
Policy Revision
The Board, based on recommendations from the Audit Committee, also approved a revised Policy for dealing in Related Party Transactions (RPT Policy).
Source: BSE
